Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 4NETWORK 3OTHER 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Rectal Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hodgkin Disease 6Congenital Abnormalities 6Colonic Neoplasms 6Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Waldenstrom Macroglobulinemia 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT01083368 2019-08-21

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Case Comprehensive Cancer Center

Phase 1/2 Completed
22 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT01338792 2014-03-10

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

University of Southern California

Phase 2 Completed
47 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡